{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:53:20Z","timestamp":1774961600753,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000357","name":"North West Cancer Research","doi-asserted-by":"publisher","award":["CR1113"],"award-info":[{"award-number":["CR1113"]}],"id":[{"id":"10.13039\/501100000357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000357","name":"North West Cancer Research","doi-asserted-by":"publisher","award":["CR1210"],"award-info":[{"award-number":["CR1210"]}],"id":[{"id":"10.13039\/501100000357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000357","name":"North West Cancer Research","doi-asserted-by":"publisher","award":["CR1011"],"award-info":[{"award-number":["CR1011"]}],"id":[{"id":"10.13039\/501100000357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007414","name":"Qassim University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["FEBS Letters"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Malignant melanoma, an aggressive skin cancer with a poor prognosis, frequently features BRAFV600E mutation resulting in activation of the MAPK pathway and melanocyte proliferation and survival. BRAFV600E inhibitors like vemurafenib and dabrafenib have enhanced patient survival, yet drug resistance remains a significant challenge. We investigated the role of the ERK5 pathway in BRAFV600E melanoma cells and cells with acquired resistance to PLX4720 (vemurafenib) and dabrafenib. In BRAFV600E melanoma, ERK5 inhibition minimally affected viability compared to ERK1\/2 inhibition. In vemurafenib\u2010resistant cells, ERK5 inhibition alone didn't impact viability or restore drug sensitivity to vemurafenib. However, in dabrafenib\u2010resistant cells, ERK5 inhibition reduced viability and enhanced the anti\u2010proliferative effect of MEK1\/2 inhibition. Targeting the ERK5 pathway may represent a therapeutic opportunity in dabrafenib\u2010resistant melanoma.<\/jats:p>","DOI":"10.1002\/1873-3468.14960","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T03:20:40Z","timestamp":1720495240000},"page":"2011-2027","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The <scp>ERK5<\/scp> pathway in <scp>BRAFV600E<\/scp> melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib"],"prefix":"10.1002","volume":"598","author":[{"given":"Anil Kumar","family":"Mondru","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Aljasir","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alrumayh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Greaves","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine","family":"Emmett","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Albohairi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowan","family":"Pritchard\u2010Jones","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-1232","authenticated-orcid":false,"given":"Michael J.","family":"Cross","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"361","article-title":"Vemurafenib: first\u2010in\u2010class BRAF\u2010mutated inhibitor for the treatment of Unresectable or metastatic melanoma","volume":"6","author":"Shelledy L","year":"2015","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q363"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100788"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071823"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.2312"},{"key":"e_1_2_9_9_1","first-page":"2725","article-title":"Dabrafenib: a\u00a0new opportunity for the treatment of BRAF V600\u2010positive melanoma","volume":"9","author":"Banzi M","year":"2016","journal-title":"Onco Targets Ther"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3392"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.017"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.839997"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.01.006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2189"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.21.12665"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.07.007"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-004-0602-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4540"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20140276"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.072801"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20110663"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.06.010"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2324"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1120915"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1609019113"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01606"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2022.09.004"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-016-1757-x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml200004g"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00072"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.09.087"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00638"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54917-1"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.10.001"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0959"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00449.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206839"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.08.001"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.08.008"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep46244"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0164-9"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.339"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4000"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml4000063"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207785"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1498"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11551"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199264"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.03.972"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129736"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.665871"}],"container-title":["FEBS Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1873-3468.14960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:36:49Z","timestamp":1724672209000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1873-3468.14960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":51,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/1873-3468.14960"],"URL":"https:\/\/doi.org\/10.1002\/1873-3468.14960","archive":["Portico"],"relation":{},"ISSN":["0014-5793","1873-3468"],"issn-type":[{"value":"0014-5793","type":"print"},{"value":"1873-3468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"2024-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}